Beta Bionics, Inc./$BBNX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Beta Bionics, Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Ticker
$BBNX
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
353
Website
BBNX Metrics
BasicAdvanced
$730M
-
-$5.66
-
-
Price and volume
Market cap
$730M
52-week high
$21.62
52-week low
$8.89
Average daily volume
567K
Financial strength
Current ratio
15.881
Quick ratio
14.585
Long term debt to equity
1.737
Total debt to equity
2.223
Profitability
EBITDA (TTM)
-53.273
Gross margin (TTM)
53.93%
Net profit margin (TTM)
-101.62%
Operating margin (TTM)
-77.96%
Revenue per employee (TTM)
$200,000
Management effectiveness
Valuation
Price to revenue (TTM)
3.015
Price to book
2.32
Price to tangible book (TTM)
2.32
Price to free cash flow (TTM)
-3.543
Free cash flow yield (TTM)
-28.23%
Free cash flow per share (TTM)
-4.74
Growth
Bulls say / Bears say
Beta Bionics successfully completed an upsized initial public offering, raising approximately $229.1 million, which enhances its financial position for further development and commercialization of its diabetes management solutions. (nasdaq.com)
Analysts from Wolfe Research initiated coverage of Beta Bionics with an 'Outperform' recommendation, indicating strong confidence in the company's growth prospects. (nasdaq.com)
Beta Bionics announced an agreement with Abbott to integrate its iLet Bionic Pancreas with Abbott's future dual glucose-ketone sensor, potentially enhancing the device's capabilities and market appeal. (stockanalysis.com)
Leerink Partners lowered their earnings estimates for Beta Bionics, projecting a Q1 2025 loss of $0.51 per share, which may indicate concerns about the company's short-term profitability. (defenseworld.net)
Despite the successful IPO, the stock has experienced a decline, with the current price at $13.52, down from the IPO price of $17.00, suggesting potential investor concerns. (stocktitan.net)
The company reported a loss of $54.76 million in 2024, a 24.2% increase from the previous year, which may raise concerns about its path to profitability. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Beta Bionics, Inc. stock?
Beta Bionics, Inc. (BBNX) has a market cap of $730M as of August 01, 2025.
What is the P/E ratio for Beta Bionics, Inc. stock?
The price to earnings (P/E) ratio for Beta Bionics, Inc. (BBNX) stock is 0 as of August 01, 2025.
Does Beta Bionics, Inc. stock pay dividends?
No, Beta Bionics, Inc. (BBNX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Beta Bionics, Inc. dividend payment date?
Beta Bionics, Inc. (BBNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Beta Bionics, Inc.?
Beta Bionics, Inc. (BBNX) does not currently have a Beta indicator.